Cargando…

RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1

Primary intracranial leiomyosarcoma (LMS) is very rare, with only a few reported cases. Only one prior case report of intracranial LMS in a patient with neurofibromatosis type 1 (NF1) was identified. We report a case of primary intracranial LMS in a patient with known history of NF1. Our patient is...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Aaron, Hoerig, Clay, Xu, Jordan, Pathare, Jody, Abongwa, Chenue, Olaya, Joffre, Plant, Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168264/
http://dx.doi.org/10.1093/neuonc/noab090.172
_version_ 1783701855882182656
author Goldberg, Aaron
Hoerig, Clay
Xu, Jordan
Pathare, Jody
Abongwa, Chenue
Olaya, Joffre
Plant, Ashley
author_facet Goldberg, Aaron
Hoerig, Clay
Xu, Jordan
Pathare, Jody
Abongwa, Chenue
Olaya, Joffre
Plant, Ashley
author_sort Goldberg, Aaron
collection PubMed
description Primary intracranial leiomyosarcoma (LMS) is very rare, with only a few reported cases. Only one prior case report of intracranial LMS in a patient with neurofibromatosis type 1 (NF1) was identified. We report a case of primary intracranial LMS in a patient with known history of NF1. Our patient is a 17-years-old female without history of immunocompromise presenting with severe headaches representative of right frontal hemorrhagic tumor found to be primary intracranial LMS. In prior reported cases, most primary intracranial LMS were treated with sarcoma-based chemotherapy and radiation therapy. Our patient underwent multiple resections, as well as focal radiation. Her chemotherapy initially included ifosfamide, carboplatin, and etoposide, but when she failed etoposide twice due to severe allergic reactions, she completed treatment successfully with the combination of ifosfamide and doxorubicin. She continues to be doing well with no evidence of disease at 41 months post-treatment.
format Online
Article
Text
id pubmed-8168264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81682642021-06-02 RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1 Goldberg, Aaron Hoerig, Clay Xu, Jordan Pathare, Jody Abongwa, Chenue Olaya, Joffre Plant, Ashley Neuro Oncol Rare Tumors/Other Primary intracranial leiomyosarcoma (LMS) is very rare, with only a few reported cases. Only one prior case report of intracranial LMS in a patient with neurofibromatosis type 1 (NF1) was identified. We report a case of primary intracranial LMS in a patient with known history of NF1. Our patient is a 17-years-old female without history of immunocompromise presenting with severe headaches representative of right frontal hemorrhagic tumor found to be primary intracranial LMS. In prior reported cases, most primary intracranial LMS were treated with sarcoma-based chemotherapy and radiation therapy. Our patient underwent multiple resections, as well as focal radiation. Her chemotherapy initially included ifosfamide, carboplatin, and etoposide, but when she failed etoposide twice due to severe allergic reactions, she completed treatment successfully with the combination of ifosfamide and doxorubicin. She continues to be doing well with no evidence of disease at 41 months post-treatment. Oxford University Press 2021-06-01 /pmc/articles/PMC8168264/ http://dx.doi.org/10.1093/neuonc/noab090.172 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Rare Tumors/Other
Goldberg, Aaron
Hoerig, Clay
Xu, Jordan
Pathare, Jody
Abongwa, Chenue
Olaya, Joffre
Plant, Ashley
RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title_full RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title_fullStr RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title_full_unstemmed RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title_short RARE-11. PRIMARY INTRACRANIAL LEIOMYOSARCOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1
title_sort rare-11. primary intracranial leiomyosarcoma in a patient with neurofibromatosis type 1
topic Rare Tumors/Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168264/
http://dx.doi.org/10.1093/neuonc/noab090.172
work_keys_str_mv AT goldbergaaron rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT hoerigclay rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT xujordan rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT patharejody rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT abongwachenue rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT olayajoffre rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1
AT plantashley rare11primaryintracranialleiomyosarcomainapatientwithneurofibromatosistype1